Providing patients and customers with
uncompromising quality and value for almost 40 years
Par is a specialty pharmaceutical company that develops, manufacture and markets innovative and cost-effective pharmaceuticals that help improve patient quality of life. Par Pharmaceutical offers a line of high barrier-to-entry generic drugs, while Par Specialty Pharmaceuticals provides niche, innovative brands. Par Sterile Products develops, manufactures and markets both branded and generic aseptic injectable pharmaceuticals.
At Par, our most important resource is the talent and dedication of our nearly 1,900 employees, each of whom is part of a culture that values integrity, customer focus, teamwork and performance. In creating a climate that encourages collaboration, Par has become the partner of choice within its industry and has built a diverse network of strategic partnerships with dozens of companies. Headquartered in Woodcliff Lake, New Jersey, Par has manufacturing and R&D facilities in Chestnut Ridge, New York, Irvine, California, Rochester, Michigan, Stratford, Connecticut and Chennai, India.
|11/12/14||Par Pharmaceutical Announces First FDA Approval of Vasostrict™ (vasopressin injection, USP)|
|Chestnut Ridge, NY, Nov. 12, 2014 – Par Pharmaceutical Companies, Inc. today announced that it has received approval for its New Drug Application (NDA) for Vasostrict™ (vasopressin injection, USP) 20 units/mL from the U.S. Food and Drug Administration (FDA) pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act. Par’s Vasostrict™ is the first and only vasopressin injection, USP, product with an NDA approved by the FDA. Vasostrict™ is indicated to increase blood ... |
|11/05/14||Par Pharmaceutical Announces Quarterly Conference Call|
|Woodcliff Lake, N.J., November 6, 2014 – Par Pharmaceutical Companies, Inc. announced today that it will host a conference call on Thursday, November 13, 2014 at 9:00 a.m. EST to review its results of operations for the third quarter ended September 30, 2014. Par is privately held and currently makes certain financial information available to the public in its filings with the Securities and Exchange Commission and will make certain other information available on its website by following t... |
|09/30/14||Par Pharmaceutical Begins Shipment of Generic Exforge®|
|Woodcliff Lake, NJ, Sept. 30, 2014 – Par Pharmaceutical Companies, Inc. today announced that it has begun shipping all four strengths of amlodipine and valsartan tablets, the generic version of Novartis’ Exforge®. Par received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for amlodipine and valsartan and was granted 180 days of marketing exclusivity. Amlodipine and valsartan is indicated for the treatment of hypertension, to l... |
|09/08/14||Par Pharmaceutical Resumes Shipment of Generic Precedex® Injection|
|Woodcliff Lake, NJ, Sept. 8, 2014 – Par Pharmaceutical Companies, Inc. today announced that it has resumed shipping dexmedetomidine hydrochloride (HCl) injection, EQ 100 mcg base/mL, the generic version of Hospira’s Precedex® Injection. Par immediately resumed shipping after a U.S. District Court lifted a temporary restraining order that was issued in August at Hospira’s request. Last month, Par received final approval from the U.S. Food and Drug Administration for its Abbre... |
|There are currently no events scheduled.|
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.